Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Student Research Poster |
| Language: | English |
| Published: |
Nanyang Technological University
2023
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/170727 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| Summary: | Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL is R-CHOP (Rituximab, Cyclophosphamide, doxorubicin hydrochloride (Hydroxy daunomycin), Oncovin, and Prednisone) chemotherapy. However, even after the treatment, only 50-60% of patients show complete response; the remaining patients suffer from progression in the form of relapse (cancer reappearing) and refractory disease (cancer stops responding to treatment). |
|---|